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Background: Bleeding complications remain a potentially important contributor to mor- 
bidity and cost I” the treatment of acute coronary syndromes (ACS). We hypothesized 
that bleeding would be associated with disease comorbidites, excess cost, and increase 
length of stay. 
Methods The TACTICS TIMI 18 enrolled 2220 patients with ACS and compared early 
invasrve and conservative management strategies on a background of Tirofiban therapy. 
Major bleeding was defined as a decrease in the blood hemoglobinlevel of at least 5.0 g 
per deciliter, the heed for the transfusion of 2 or more units of blood, the need for coro- 
nary artery bypass grafting (CABG). tamponade during the index hospitalization. 
Results: Major bleeding occurred in 4.4% of all patients. 14.4% of CABG patients, 2.4% 
of non-CABG patients, and 4.7% of PCI patients. Intracranial hemorrhage occurred in 
one patient. Vascular access site bleeding occurred in 0.4% of all patients and in 1.5% of 
PCI patients. Increased age, lower weight, ST deviation, positive troponin status, an 
early invasive strategy, angiography during the initial hospitalization. emergent PCI, and 
CABG were all associated with major bleeding in univariate analysis. Only CABG and 
Age ~65 were independently associated with major bleeding in the multivariate analysis. 
After adjustment for CABG, age>65, positive troponin status, diabetes, and ST deviation, 
major bleeding was independently associated with an increased risk of death at 30 days 
(OR 5.0, p<O.OOi). Major bleeding was associated with $6,596 per patient of excess ini- 
tial hospitalization costs, and 1.2 days per patient increase in length of stay (after adjust- 
ment for potential confounding variables). 
Conclusions: Major bleeding occurred infrequently despite a high rate of invasive revas- 
cularization procedures. Major bleeding is associated with excess costs, increased 
length of stay, and higher mortality. 
1146-109 Renal Insufficiency in the Setting of an Acute Coronary 
Syndrome Is Associated With a Marked Increase in 
Death and Myocardial Infarction at 30 days 
Background: Re-infarction (reMI) is associated with worse outcomes following fibrin- 
olytic therapy and is increasingly a component of the primary endpoint in clinical trials In 
2001, 3 large clinical trials reported that reMl was reduced in patients receiving the 
experimental reperfusion and adjunctive therapies. In HERO-2, which randomized 
patients to receive either intravenous heparin or bivalirudin prior to streptokinase, reMl 
was adjudicated by a Cknical Endpoints Commrttee (CEC) and we report the results of 
reMl adjudication. Methods: Adjudication was performed on data collected by investiga- 
tors according to the following pre-defined criteria: i) ~18 hours from randomization 
(230min chest pain and ZlmV ST elevation in 2 leads), ii) 18 hours from randomzation 
(CK level >2x upper limit of normal (ULN)or CKMB >ULN and >50% above prior base- 
line, iii) in association with percutaneous intervention (CK or CKMB levels z-3x ULN) or iv) 
surgical revascularization (CK or CKMB levels >5x ULN); also in Ii-iv new LBBB or new Q 
waves. Results: Of 722 cases referred for CEC adjudication of reMI, 170 cases (24%) 
reMl was not confirmed for the following reasons: 57 (34%) sufficient data available for 
CEC to determine “no reMI”; 43 (25%) lack of data supplied to confirm reMI; 19 (11%) 
recurrent ST elevation at >18 hours but reperfusion therapy (6 PCI) and no CKfCKMB 
elevation; 16 (9%) died prior to possible CWCKMB level elevations; and 35 (20%) had a 
CEC-adjudicated non-ischemic etiology. 30-day mortalities for adjudicated, investigator- 
reported reMIs, and no reMl were 24%, 27% and 10% (pcO.001) and mortalities for adju- 
dicated reMIs at c96 hours, >96 hours were 28%, and 19% (~~0.04). Rates of reMl dif- 
fered across 5 regrons at (predefined) 96 hours (highest Western Countries 3.2%, lowest 
Eastern Europe 1.5% p<O.oOi), partly reflecting different rates of reMl at cl8 hours 
(highest Asia 1 .l%, lowest Russia 0.23%; pcO.001). Conclusion: Despite prespecified 
criteria for investigators, 24% of cases were adjudicated “no reMI” by the CEC. ReMl var- 
ied markedly by region, especially at c96 hours compared to later than this time after ran- 
domization, and reMl mortality varied over these time periods. 
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Background: Renal insufficiency (RI) is an established predictor of long-term outcome in 
patrents with coronary artery disease. The impact of RI on short-term outcomes following 
hospitalization for an acute coronary syndrome (ACS) remains unknown. We sought to 
investigate whether RI at the time of presentation with an ACS predicted clinical events 
at 30 days. Methods: Using an interventional registry database, 504 patients presenting 
wrth an ACS were grouped into one of four categories based on creatinine clearance 
(CrCI) in mllmin: >90, 60-90, 30-60, and ~30. Patient outcomes were recorded at 30 days 
and 1 year. Results: Using a test of trend and homogeneity, we observed an exponential 
rise in the risk of death and Ml at 30 days for each decrement in renal function (X2=32, 
p~O.O000l)(graph). Patients were then divided into two groups classified as normal 
(CrCIx60) or RI (CrClc60). When compared to normals, patients with renal insufficiency 
suffered a 5-fold excess of death or MI at 30 days (OR 5.23[C.l.=2.57-10.661, 
p<O.OOOOl). Conclusion: The prevalence of RI (defined as CrCIc60) was 28% in this 
ACS population, and conferred a 5fold increased risk of death and Ml at 30 days. The 
prevalence and impact of RI is therefore equal to, or greater than, many of the commonly 
utilized biomarkersfor risk assessment in ACS. This suggests that the presence of RI 
should weigh heavily in the overall risk assessment of ACS patients. 
Background: Patients (Pts) who develop thrombocytopenia (tcp) associated with heparin 
or Ilb/llla inhibitors have increased risk of bleeding events as well as myocardial infarc- 
tion (Ml) and death (Circl999). Pts with relative tcp at baseline are at higher risk to 
develop significant tcp. In a consecutive series, 15.6% of pts with Ml had a platelet (plt) 
count of <150.000 at presentation, increased bleeding and ischemic complications com- 
pared to pts with normal plt counts. Bivalirudin, a direct thrombin inhibitor that does hot 
cause tcp. has been shown to decrease bleeding and ischemic complications compared 
to heparin during PCI. Methods: We compared the outcome of pts with relative tcp in 
1,425 pts treated with bivalirudin vs. heparin during PCI. From a database of 4,763 pts 
enrolled in 5 trials of brvalirudin vs. heparin in conjunction with PCI, 236 (5%) pts had a 
plt count <I 50,000 and 1,425 (29.8%) had a plt count ~200,000 at the time of the PCI. 
Pts treated with bivalirudin had lower incidence of death, MI, revascularization, or major 
hemorrhage (see table). Conclusions: Relative tcp (~200,000) is relatively common even 
for pts enrolled in randomized clinical thals. Pts treated wtih bivalirudin had significantly 
lower incidence of death, MI, revasculanzation. or major hemorrhage. The overall out- 
come and magnitude of benefit with bivalirudln were similar to pts wrth a plt count 
>200,000 at baseline. Relative tcp does not appear to be a risk factor for adverse out- 
come among pts treated with bivalirudin. 
30 
Event Bivalirudin Heparin 0 95%CI 
(rl=745) @=sso) R 
Death, MI, Revascularization or Major 47 (6.3%) 72 (10.6%) 0. 0.39, 
Hemorrhage 57 0.63 
Death or MI 22 (3.0%) 30 (4.4%) 0. 0.38, 
66 1.15 
Revascularization 14 (1.9%) 18 (2.6%) 0. 0.35, 
70 1.43 
Major Hemorrhage 19 (2.6%) 37 (5.4%) 0. 0.26, 
45 0.80 
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Background: Risk factors for nonhemorrhagic cerebrovascular accidents (NHCVA) in the 
setting of myocardral infarction (Ml) have been described. To date no study has evalu- 
ated oender-soacific risk factors for NHCVA. Methods: Analvsis of the National Reaistrv _ _ , 
of Myocardial Infarction (NRMI) 314 databases shows that women are 64% more likely to 
suffer NHCVA with Ml than are men. This difference oersists desoite controllino for 27 
variables using a multivariate model (OR for women vs. men 1.431, 95% Cl 1.285. 
1.593). We analyzed records of 257,637 male and 197,865 female patients with MI found 
in the NRMI 3/4 databases. Of these 997 males (0.388%) and 1250 females (0.636%) 
suffered NHCVA. Females with NHCVA were significantly more likely to be older, have a 
